| Schedule Of research and development expenses have been disaggregated |
The significant expense categories within net loss are presented on the condensed consolidated statements of operations. Research and development expenses have been disaggregated as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Tarcocimab program expenses |
|
$ |
9,406 |
|
|
$ |
11,886 |
|
|
$ |
19,351 |
|
|
$ |
26,162 |
|
KSI-501 program expenses |
|
|
12,746 |
|
|
|
3,862 |
|
|
|
22,603 |
|
|
|
7,162 |
|
KSI-101 program expenses |
|
|
12,279 |
|
|
|
1,447 |
|
|
|
19,279 |
|
|
|
2,364 |
|
ABC Platform and other program expenses |
|
|
3,607 |
|
|
|
6,421 |
|
|
|
7,373 |
|
|
|
12,066 |
|
Payroll and personnel expenses |
|
|
13,672 |
|
|
|
14,109 |
|
|
|
27,851 |
|
|
|
28,379 |
|
Facilities and other research and development expenses |
|
|
4,373 |
|
|
|
5,035 |
|
|
|
8,173 |
|
|
|
10,271 |
|
Total research and development expenses |
|
$ |
56,083 |
|
|
$ |
42,760 |
|
|
$ |
104,630 |
|
|
$ |
86,404 |
|
|